Evidence map›Paper›PMID 30627668›Full record

ArticleInternational journal of respiratory and pulmonary medicine2018

A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Daniel E Fenker, Cameron T McDaniel, Warunya Panmanee, Ralph J Panos, Eric J Sorscher, Carleen Sabusap, John P Clancy, Daniel J Hassett

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of respiratory and pulmonary medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025
    Review
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis.Diagnostics (Basel, Switzerland) · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Daniel E FenkerDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, USA.
Cameron T McDanielDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, USA.
Warunya PanmaneeDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, USA.
Ralph J PanosDepartment of Medicine, Cincinnati VA Medical Center, Cincinnati, USA.
Eric J SorscherDepartment of Pediatrics, Emory University, Atlanta, USA.
Carleen SabusapDepartment of Pediatrics, Emory University, Atlanta, USA.
John P ClancyDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, USA.
Daniel J HassettDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, USA.
University of Cincinnati Medical Center · USEmory University · USCincinnati Children's Hospital Medical Center · USCincinnati VA Medical Center · US

Funding

Ribosomal perturbation as a mechanism to prevent misfolding of CFTRR01HL136414 · NHLBI · EMORY UNIVERSITY · PI HARTMAN, JOHN L, SORSCHER, ERIC J · 2018 to 2025
$4.5M
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicineR01HL139876 · NHLBI · EMORY UNIVERSITY · PI DAVIS, BRIAN R., SORSCHER, ERIC J · 2018 to 2022
$3.8M
MR predictors of infection, inflammation, and structural lung damage in CFR01HL116226 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI CLANCY, JOHN PAUL · 2012 to 2015
$2.1M
Mechanism Underlying Nitrite Sensitivity of Mucoid Pseudomonas in COPDI01BX000845 · VA · CINCINNATI VA MEDICAL CENTER RESEARCH · PI HASSETT, DANIEL J. · 2011 to 2013
–
BLRD VA I01 BX000845NHLBI NIH HHS R01 HL116226NHLBI NIH HHS R01 HL136414NHLBI NIH HHS R01 HL139876
6 · The paper itself

Abstract

Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are chronic pulmonary diseases that affect ~70,000 and 251 million individuals worldwide, respectively. Although these two diseases have distinctly different pathophysiologies, both cause chronic respiratory insufficiency that erodes quality of life and causes significant morbidity and eventually death. In both CF and COPD, the respiratory microbiome plays a major contributing role in disease progression and morbidity. Pulmonary pathogens can differ dramatically during various stages of each disease and frequently cause acute worsening of lung function due to disease exacerbation. Despite some similarities, outcome and timing/type of exacerbation can also be quite different between CF and COPD. Given these clinical distinctions, both patients and physicians should be aware of emerging therapeutic options currently being offered or in development for the treatment of lung infections in individuals with CF and COPD. Although interventions are available that prolong life and mitigate morbidity, neither disorder is curable. Both acute and chronic pulmonary infections contribute to an inexorable downward course and may trigger exacerbations, culminating in loss of lung function or respiratory failure. Knowledge of the pulmonary pathogens causing these infections, their clinical presentation, consequences, and management are, therefore, critical. In this review, we compare and contrast CF and COPD, including underlying causes, general outcomes, features of the lung microbiome, and potential treatment strategies.

Indexed as

BiofilmsChronic obstructive pulmonary diseaseCystic fibrosisInfectionMicrobiology

Identifiers

PMID30627668
PMCPMC6322854
OpenAlexW2905016081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.